A Phase 3 interventional study of Esketamine and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 61 sites in 12 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing esketamine in Depressive Disorder, Major — 5 open to participants now, 5 under way, 2 of them phase 3. Esketamine · Depressive Disorder, Major.
Among the 17 studies testing esketamine in Depressive Disorder, Major, this one is the 4th largest by enrollment, is one of 3 that started in 2017, is one of 7 in phase 3, and was the 5th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →5 of the 17 studies testing esketamine in Depressive Disorder, Major are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States, Brazil, Hungary and 4 more countries
Ages 12–17
Dr. Inge Winter · Sites in Austria, Germany, Greece and 3 more countries
Ages 18–65
Royal North Shore Hospital · Sites in Australia
Ages 18–65
Massachusetts General Hospital · Sites in United States
Ages 18–70
Medical University of Vienna · Sites in Austria
Ages 18–55 · Healthy volunteers
By country, each count listing its studies:
Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 230 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 147 across the 17 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
59 studies in Depressive Disorder, Major by Johnson & Johnson: 5 open now, 5 under way, 5 of them phase 3. Of 53 finished, 26 (49%) have results posted.
Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 22nd largest by enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2017, is one of 23 in phase 3, and was the 26th registered.
Johnson & Johnson’s Depressive Disorder, Major studies by the year they started, since 2002.
1 of the studies testing esketamine in Depressive Disorder, Major that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05450432Massachusetts General HospitalLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing esketamine in Depressive Disorder, Major, from their registry updates:
Among Johnson & Johnson’s 59 in Depressive Disorder, Major:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of intranasal esketamine 84 milligram (mg) compared with intranasal placebo in addition to comprehensive standard of care in reducing the symptoms of Major Depressive Disorder (MDD), including suicidal ideation, in participants who are assessed to be at imminent risk for suicide, as measured by the change from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) total score at 24 hours post first dose.
If you or a loved one are having thoughts of suicide, please seek immediate medical help. Go to the emergency room or call the National Suicide Prevention Lifeline at 1-800-273-8255.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intranasal esketamine 84 milligram (mg) on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
Drug: Esketamine · Other: Standard of Care
Participants will receive intranasal placebo on Day 1, 4, 8, 11, 15, 18, 22, and 25 along with standard of care antidepressant treatment.
Drug: Placebo · Other: Standard of Care
Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase
Clinical global impression-severity of suicidality-revised (CGI-SS-R) scale is revised version of the clinical global impression severity scale (CGI-S),a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1, predose) and 24 hours first post dose (Day 2)
Number of Participants With Remission of Major Depressive Disorder (MADRS Total Score Less Than or Equal to [<=] 12): DB Treatment Phase
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.
Time frame: Days 1 (4 hours [h] postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
Change From Baseline in MADRS Total Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
MADRS is a clinician-rated scale designed to be used in participants with MDD to measure depression severity and detect changes due to antidepressant treatment. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The instrument consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25 (predose and 4 hours postdose)
Change From Baseline in CGI-SS-R Score at 4 Hours Post First Dose at Day 1 (4 Hours Post First Dose), and 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. A higher score indicates a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Number of Participants Who Achieved Resolution of Suicidality (CGI-SS-R Score of 0 or 1): DB Treatment Phase
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. A participant was considered to have achieved resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). Participants who did not met such criterion or discontinued prior to the time point for any reason were not considered to have resolution of suicidality.
Time frame: Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Change From Baseline in Clinical Global Impression of Imminent Suicide Risk (CGI-SR-I) at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.
Time frame: Baseline (Day 1, predose), Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Change From Baseline in Beck Hopelessness Scale (BHS) Total Score at Days 8 and 25 in DB Treatment Phase
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.
Time frame: Baseline, Days 8 and 25
Change From Baseline in European Quality of Life Group, 5-Dimension, 5-Level (EQ-5D-5L) Sum Score at Days 2, 11 and 25 of the DB Treatment Phase
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (no problem, slight, moderate, severe and extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst imaginable health)-100 (best imaginable health). Sum score ranges from 0 -100. Sum score=(sum of the scores from the 5 dimensions minus 5)\*5. Higher score indicates worse health state. Negative change in score indicates improvement.
Time frame: Baseline, Days 2, 11 and 25
Change From Baseline in European Quality of Life Group, Visual Analogue Scale (EQ-VAS) Score at Days 2, 11 and 25 of the DB Treatment Phase
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Positive change in score indicates improvement.
Time frame: Baseline, Days 2, 11 and 25
Change From Baseline in EQ-5D-5L Health Status Index at Days 2, 11 and 25 of the DB Treatment Phase
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). Positive change in score indicates improvement.
Time frame: Baseline, Days 2, 11 and 25
Change From Baseline in Quality of Life in Depression Scale (QLDS) Total Score at Days 2, 11 and 25 of the DB Treatment Phase
The QLDS is a disease-specific patient-reported outcome designed to assess health-related quality of life in patients with MDD, it captures the impact of depression and its treatment from the participant's perspective. The instrument has a recall period of "at the moment" and contains 34 items with "true"/"not true" response options. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.
Time frame: Baseline, Days 2, 11 and 25
Treatment Satisfaction Questionnaire for Medication (TSQM-9) Domain Score at Days 15 and 25: DB Treatment Phase
The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = \[(item 1 + item 2 + item 3) - 3\]/18\*100, (ii) Convenience = \[(item 4 + item 5 + item 6) - 3\]/18\*100 and (iii) Global satisfaction = \[(item 7 + item 8 + item 9) - 3\]/14\*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction.
Time frame: Days 15 and 25
Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 5 (My Risk) Question 3 (Participant-Reported Frequency of Suicidal Thinking) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time).
Time frame: Baseline, Days 1 (4h postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Change From Baseline in Suicide Ideation and Behavior Assessment Tool (SIBAT) Module 7 (Clinician-rated Frequency of Suicidal Thinking [FoST]) Score at Days 1, 2, 4, 8, 11, 15, 18, 22 and 25: DB Treatment Phase
SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement.
Time frame: Baseline, Days 1 (4 hours postdose), 2, 4, 8, 11, 15, 18, 22 and 25
Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent.
Time frame: Up to Day 25
Number of Participants With Treatment Emergent Abnormal Laboratory Values: DB Treatment Phase
Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin (low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine (High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0\*1012/L,high=6.4\*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5\*109/L,high=15.5\*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100\*109/L,high=600\*109/L\]; Potassium(low=3.0mmol/L,high=5.8 mmol/L\]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH).
Time frame: Up to Day 25
Number of Participants With Abnormal Nasal Examinations at Day 25: DB Treatment Phase
Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed.
Time frame: At Day 25
Number of Participants With Treatment Emergent Abnormal Electrocardiogram (ECG) Values at Any Time: DB Treatment Phase
Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\] , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec) were reported.
Time frame: Up to Day 25
Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase
Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (\<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to \>= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported.
Time frame: Up to Day 25
Number of Participants With Treatment Emergent Vital Signs Abnormalities: DB Treatment Phase
Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm \[abnormally low = a decrease from baseline of \>= 15 to a value \<= 50; abnormally high = an increase from baseline of \>=15 to a value \>=100\] , systolic blood pressure \[SBP\] in mmHg \[abnormally low = a decrease from baseline of \>= 20 to a value \<= 90; abnormally high = an increase from baseline of \>= 20 to a value \>= 180\], and diastolic blood pressure \[DBP\] in mmHg \[abnormally low= a decrease from baseline of \>=15 to a value \<= 50; abnormally high = an increase from baseline of \>= 15 to a value \>= 105) were reported.
Time frame: Up to Day 25
Number of Sedated Participants as Assessed by Modified Observer's Assessment of Alertness/Sedation (MOAA/S) Score at Any Time: DB Treatment Phase
MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation.
Time frame: Up to Day 25
Number of Participants With an Increase in Clinician-administered Dissociative States Scale (CADSS) Total Score Over Time: DB Treatment Phase
The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of \> 0) was reported.
Time frame: Days 1, 4, 8, 11, 15, 18, 22 and 25
| Milestone | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Started | 115 | 115 |
| Treated | 113 | 114 |
| Completed | 85 | 81 |
| Not completed | 30 | 34 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Discontinued db, not entered fu phase | 21 | 25 |
| Withdrew: Other | 3 | 2 |
| Withdrew: Adverse event | 1 | 0 |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 24 Hours Post First Dose (Last Observation Carried Forward [LOCF] Data): Double-blind (DB) Treatment Phase | -12.4 ± 10.43 | -15.7 ± 11.56 |
Clinical global impression-severity of suicidality-revised (CGI-SS-R) scale is revised version of the clinical global impression severity scale (CGI-S),a global rating scale that gives an overall measure of the severity of a participants illness. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change From Baseline in Clinical Global Impression-Severity of Suicidality - Revised (CGI-SS-R) Scale at 24 Hours Post First Dose (LOCF Data): DB Treatment Phase | -1.0 (-5 to 2) | -1.0 (-6 to 2) |
MADRS is clinician-rated scale designed to be used in participants with Major Depressive Disorder (MDD) to measure depression severity and detect changes due to antidepressant treatment. It evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic and suicidal thoughts. Scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of symptoms), summed for total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Day 1: 4 hours post dose | 4 | 12 |
| Day 2 | 12 | 25 |
| Day 4 | 20 | 26 |
| Day 8 | 23 | 28 |
| Day 11 | 26 | 32 |
| Day 15 | 29 | 36 |
| Day 18 | 32 | 29 |
| Day 22 | 37 | 42 |
| Day 25: Predose | 31 | 49 |
| Day 25: 4 hours postdose | 42 | 54 |
MADRS is a clinician-rated scale designed to be used in participants with MDD to measure depression severity and detect changes due to antidepressant treatment. MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The instrument consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 0 to 60. Higher scores represent a more severe condition. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 1: 4 hours postdose | -8.2 ± 7.62 | -12.2 ± 9.87 |
| Change at Day 2 | -12.4 ± 10.51 | -16.0 ± 11.52 |
| Change at Day 4 | -15.7 ± 11.50 | -17.7 ± 11.94 |
| Change at Day 8 | -17.4 ± 11.29 | -20.1 ± 11.47 |
| Change at Day 11 | -19.5 ± 11.60 | -21.3 ± 11.45 |
| Change at Day 15 | -20.0 ± 12.54 | -23.4 ± 10.62 |
| Change at Day 18 | -21.4 ± 12.90 | -23.1 ± 11.39 |
| Change at Day 22 | -22.0 ± 12.12 | -24.5 ± 11.57 |
| Change at Day 25: Predose | -22.5 ± 12.23 | -26.2 ± 11.09 |
| Change at Day 25: 4 hours postdose | -26.4 ± 11.18 | -28.7 ± 10.88 |
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. A higher score indicates a more severe condition. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 1: 4 hours postdose | -1.0 (-4 to 1) | -1.0 (-6 to 1) |
| Change at Day 2 | -1.0 (-5 to 2) | -1.0 (-6 to 2) |
| Change at Day 4 | -2.0 (-5 to 2) | -2.0 (-6 to 1) |
| Change at Day 8 | -2.0 (-5 to 2) | -2.0 (-5 to 2) |
| Change at Day 11 | -2.0 (-6 to 2) | -3.0 (-6 to 1) |
| Change at Day 15 | -3.0 (-5 to 2) | -3.0 (-6 to 0) |
| Change at Day 18 | -3.0 (-6 to 1) | -3.0 (-5 to 0) |
| Change at Day 22 | -3.0 (-5 to 3) | -3.0 (-5 to 0) |
| Change at Day 25 | -3.0 (-6 to 4) | -3.0 (-6 to 0) |
CGI-SS-R is revised version of the CGI-S. The CGI-SS-R summarizes the clinician's overall impression of severity of suicidality on a 7-point scale from 0 (normal, not at all suicidal) to 6 (among the most extremely suicidal participants), based on the totality of information available to the clinician. Higher score indicates a more severe condition. A participant was considered to have achieved resolution of suicidality at a given time point if the CGI-SS-R score was 0 (normal, not at all suicidal) or 1 (questionably suicidal). Participants who did not met such criterion or discontinued prior to the time point for any reason were not considered to have resolution of suicidality.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Day 1: 4 hours postdose | 20 | 38 |
| Day 2 | 35 | 36 |
| Day 4 | 51 | 52 |
| Day 8 | 54 | 53 |
| Day 11 | 58 | 62 |
| Day 15 | 58 | 65 |
| Day 18 | 59 | 62 |
| Day 22 | 65 | 68 |
| Day 25 | 66 | 69 |
The CGI-SR-I is a scale summarizing the clinician's best assessment of the likelihood that the participant will attempt suicide in the next 7 days. The CGI-SR-I rating is scored on a 7-point scale: where' 0 (no imminent suicide risk); 1 (minimal imminent suicide risk), 2 (mild imminent suicide risk), 3 (moderate imminent suicide risk), 4 (marked imminent suicide risk), 5 (severely imminent suicide risk), 6 (extreme imminent suicide risk). Higher score indicates a more severe condition. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 1: 4 hours postdose | 0.0 (-4 to 2) | -1.0 (-6 to 3) |
| Change at Day 2 | -1.0 (-4 to 2) | -1.0 (-6 to 2) |
| Change at Day 4 | -2.0 (-5 to 2) | -2.0 (-6 to 1) |
| Change at Day 8 | -2.0 (-5 to 2) | -2.0 (-5 to 2) |
| Change at Day 11 | -2.0 (-5 to 1) | -2.0 (-6 to 2) |
| Change at Day 15 | -3.0 (-5 to 2) | -2.0 (-6 to 1) |
| Change at Day 18 | -3.0 (-5 to 2) | -3.0 (-5 to 1) |
| Change at Day 22 | -3.0 (-5 to 2) | -3.0 (-5 to 0) |
| Change at Day 25 | -3.0 (-5 to 2) | -3.0 (-6 to 1) |
BHS is a self-reported measure to assess one's level of negative expectations or pessimism regarding future. It consists of 20 true-false items that examine respondent's attitude over past week by either endorsing a pessimistic statement or denying an optimistic statement; 9 are keyed false and 11 are keyed true. For every statement, each response was assigned score of 0 or 1. Total BHS score is sum of item responses, ranged from 0-20, where higher score represented higher level of hopelessness.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 8 | -6.3 ± 6.31 | -6.1 ± 6.17 |
| Change at Day 25 | -7.0 ± 6.47 | -8.0 ± 6.31 |
EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (no problem, slight, moderate, severe and extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ-VAS self-rating records respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst imaginable health)-100 (best imaginable health). Sum score ranges from 0 -100. Sum score=(sum of the scores from the 5 dimensions minus 5)\*5. Higher score indicates worse health state. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 2 | -9.0 ± 12.30 | -11.8 ± 14.45 |
| Change at Day 11 | -15.1 ± 16.32 | -15.0 ± 15.51 |
| Change at Day 25 | -15.3 ± 15.78 | -18.8 ± 16.96 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine). Positive change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 2 | 9.7 ± 15.57 | 13.4 ± 22.58 |
| Change at Day 11 | 17.6 ± 24.87 | 21.4 ± 26.95 |
| Change at Day 25 | 18.6 ± 25.39 | 27.0 ± 27.54 |
EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health "today". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). Positive change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 2 | 0.129 ± 0.1732 | 0.160 ± 0.1872 |
| Change at Day 11 | 0.194 ± 0.2173 | 0.202 ± 0.2051 |
| Change at Day 25 | 0.194 ± 0.2149 | 0.235 ± 0.2228 |
The QLDS is a disease-specific patient-reported outcome designed to assess health-related quality of life in patients with MDD, it captures the impact of depression and its treatment from the participant's perspective. The instrument has a recall period of "at the moment" and contains 34 items with "true"/"not true" response options. The total score range is from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition. Negative change indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 2 | -2.5 ± 3.93 | -3.5 ± 4.93 |
| Change at Day 11 | -5.2 ± 5.55 | -5.1 ± 6.16 |
| Change at Day 25 | -5.5 ± 6.03 | -6.3 ± 6.26 |
The TSQM-9 is a 9-item generic patient-reported outcome instrument to assess participants' satisfaction with medication. It covers domains of effectiveness, convenience, and global satisfaction. The TSQM-9 domain scores were calculated as recommended by the instrument authors. (i) Effectiveness = \[(item 1 + item 2 + item 3) - 3\]/18\*100, (ii) Convenience = \[(item 4 + item 5 + item 6) - 3\]/18\*100 and (iii) Global satisfaction = \[(item 7 + item 8 + item 9) - 3\]/14\*100. Each domain score can be calculated only if all the three items considered in the calculation of that score are not missing. The TSQM-9 domain score ranges from 0 to 100, with higher scores representing higher satisfaction.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Effectiveness: Day 15 | 55.3 ± 27.93 | 63.5 ± 26.05 |
| Effectiveness: Day 25 | 54.8 ± 28.84 | 68.8 ± 25.41 |
| Convenience: Day 15 | 77.2 ± 16.73 | 71.3 ± 18.38 |
| Convenience: Day 25 | 76.9 ± 17.92 | 77.0 ± 18.66 |
| Global Satisfaction: Day 15 | 59.7 ± 27.12 | 63.6 ± 27.69 |
| Global Satisfaction: Day 25 | 56.8 ± 28.31 | 71.5 ± 24.85 |
SIBAT is an assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT is organized into 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Patient-reported section has modules of demographics and suicide history, risk/protective factors, suicidal thinking, suicide behavior, and suicide risk. Question 3 from Module 5 asks participants to describe their thinking about suicide right now from 5 response options ranging from 0 (I have no suicidal thoughts) to 4 (I have suicidal thoughts all of time).
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 1: 4 hours postdose | -1.0 (-3 to 1) | -1.0 (-4 to 2) |
| Change at Day 2 | -1.0 (-4 to 1) | -1.0 (-4 to 2) |
| Change at Day 4 | -1.0 (-4 to 1) | -1.0 (-4 to 4) |
| Change at Day 8 | -2.0 (-4 to 1) | -2.0 (-4 to 4) |
| Change at Day 11 | -2.0 (-4 to 1) | -2.0 (-4 to 4) |
| Change at Day 15 | -2.0 (-4 to 0) | -2.0 (-4 to 1) |
| Change at Day 18 | -2.0 (-4 to 2) | -2.0 (-4 to 3) |
| Change at Day 22 | -2.0 (-4 to 1) | -2.0 (-4 to 3) |
| Change at Day 25 | -2.0 (-4 to 1) | -2.0 (-4 to 4) |
SIBAT is assessment tool that captures suicidal ideation, behavior, and risk. It permits assessment of change in suicidal ideation and behavior and documents clinician assessment of severity of suicidality and suicide risk. SIBAT has 8 modules divided into 2 major divisions: patient-reported section (Modules 1-5) and clinician-rated section (Modules 6-8). Clinician-rated section has modules for semi-structured interview, clinical global impressions of current severity of suicidality and imminent suicide risk, clinical global impression of long-term suicide risk, and clinical judgment of optimal suicide management. The score anchor point as in participant report frequency of suicidal thinking that is, response options from never to all the time. Module 7-FoST score ranges from 0-5; higher score indicates more severe condition. Negative change in score indicates improvement.
| units on a scale | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Change at Day 1: 4 hours postdose | -1.0 (-4 to 2) | -1.0 (-5 to 1) |
| Change at Day 2 | -1.0 (-5 to 1) | -1.0 (-5 to 1) |
| Change at Day 4 | -2.0 (-5 to 1) | -2.0 (-5 to 1) |
| Change at Day 8 | -2.0 (-4 to 1) | -2.0 (-5 to 1) |
| Change at Day 11 | -2.0 (-5 to 2) | -2.0 (-5 to 1) |
| Change at Day 15 | -2.0 (-5 to 2) | -3.0 (-5 to 0) |
| Change at Day 18 | -2.0 (-5 to 1) | -3.0 (-5 to 1) |
| Change at Day 22 | -2.0 (-5 to 2) | -3.0 (-5 to 2) |
| Change at Day 25 | -2.0 (-5 to 4) | -3.0 (-5 to 2) |
An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE is categorized as related if assessed by the investigator as possibly, probably, or very likely related to study agent.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs): DB Treatment Phase | 87 | 104 |
Low/high abnormal values are: Alanine aminotransferase (ALT)-high=200 Units per liter(U/L); ALP-high=250U/L; aspartate aminotransferase(AST)-high=250U/L; gamma glutamyl transferase(GGT)=300U/L; Albumin (low=24g/L,high=60 g/L); Bicarbonate(low=15.1, high=34.9mmol/L); Bilirubin(high=51.3micromol/L); calcium(low=1.5,high=3mmol/L);Chloride(low=94,high=112mmol/L); CK(High=990U/L); Creatinine (High=265.2micromol/L); Eosinophils(High=10%); Erythrocytes(low=3.0\*1012/L,high=6.4\*1012/L); Glucose(low=2.2,high=16.7mmol/L); Hemoglobin(low=80g/L,high=190g/L);Hematocrit(low=0.28, high=0.55 fraction); LD(high=500U/L); Leukocytes(low=2.5\*109/L,high=15.5\*109/L); Lymphocytes(low=10%,high=60%); Monocytes(high=20%); Neutrophils(low=30%,high=90%); Phosphate(low=0.7 mmol/L,high=2.6mmol/L); Platelet count(low=100\*109/L,high=600\*109/L\]; Potassium(low=3.0mmol/L,high=5.8 mmol/L\]; Protein(low=50 g/L); Sodium(low=125 mmol/L,high=155 mmol/L); Urate(low=89.2 micromol/L,high=594.8micromol/L); Urine(high=8.0 pH).
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| ALT: ALT>3*ULN | 2 | 2 |
| ALT: Abnormal High | 0 | 0 |
| Albumin: Abnormal High | 0 | 0 |
| Albumin: Abnormal Low | 0 | 0 |
| Alkaline phosphatase (ALP): Abnormal High | 0 | 0 |
| AST: AST>3*ULN | 0 | 0 |
| AST: Abnormal High | 0 | 0 |
| Bicarbonate: Abnormal High | 0 | 0 |
| Bicarbonate: Abnormal Low | 0 | 0 |
| Bilirubin: Abnormal High | 0 | 0 |
| Calcium: Abnormal High | 0 | 0 |
| Calcium: Abnormal Low | 0 | 0 |
| Chloride: Abnormal High | 0 | 0 |
| Chloride: Abnormal Low | 0 | 0 |
| Creatine Kinase (CK): Abnormal High | 0 | 0 |
| Creatinine: Abnormal High | 0 | 0 |
| GGT: Abnormal High | 3 | 1 |
| Glucose: Abnormal High | 0 | 1 |
| Glucose: Abnormal Low | 0 | 0 |
| ALT>3*ULN or AST>3*ULN and BILI>2*ULN | 0 | 0 |
| Lactate Dehydrogenase (LD): Abnormal High | 0 | 0 |
| Phosphate: Abnormal High | 0 | 0 |
| Phosphate: Abnormal Low | 0 | 1 |
| Potassium: Abnormal High | 1 | 0 |
| Potassium: Abnormal Low | 0 | 0 |
| Protein: Abnormal Low | 0 | 0 |
| Sodium: Abnormal High | 0 | 0 |
| Sodium: Abnormal Low | 0 | 0 |
| Urate: Abnormal High | 0 | 0 |
| Urate: Abnormal Low | 0 | 0 |
| Basophils: Abnormal High | 0 | 0 |
| Eosinophils: Abnormal High | 0 | 0 |
| Erythrocytes: Abnormal High | 0 | 1 |
| Erythrocytes: Abnormal Low | 0 | 0 |
| Hematocrit: Abnormal High | 0 | 2 |
| Hematocrit: Abnormal Low | 0 | 0 |
| Hemoglobin (Hb): Abnormal High | 0 | 1 |
| Hemoglobin: Abnormal Low | 0 | 0 |
| Leukocytes: Abnormal High | 1 | 0 |
| Leukocytes: Abnormal Low | 0 | 0 |
| Lymphocytes: Abnormal High | 0 | 0 |
| Lymphocytes: Abnormal Low | 2 | 1 |
| Monocytes: Abnormal High | 0 | 0 |
| Neutrophils: Abnormal High | 0 | 0 |
| Neutrophils: Abnormal Low | 0 | 1 |
| Platelets: Abnormal High | 0 | 0 |
| Platelets: Abnormal Low | 0 | 1 |
| Urine pH: Abnormal High | 0 | 0 |
Number of participants with abnormal nasal examination were reported. Nasal examination of visual inspection of the epistaxis, nasal crusts, nasal discharge, and nasal erythema was performed.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Epistaxis: Mild | 1 | 1 |
| Epistaxis: Moderate | 0 | 0 |
| Epistaxis: Severe | 0 | 0 |
| Nasal Crusts: Mild | 0 | 1 |
| Nasal Crusts: Moderate | 0 | 0 |
| Nasal Crusts: Severe | 0 | 0 |
| Nasal Discharge: Mild | 0 | 1 |
| Nasal Discharge: Moderate | 0 | 0 |
| Nasal Discharge: Severe | 0 | 0 |
| Nasal Erythema: Mild | 1 | 4 |
| Nasal Erythema: Moderate | 1 | 0 |
| Nasal Erythema: Severe | 0 | 0 |
Number of participants with treatment emergent abnormal ECG values for variables including heart rate (abnormally low refers to less than or equal to \[\<=\] 50 beats per minute \[bpm\] , abnormally high refers greater than or equal to \[\>=\] 100 bpm), pulse rate (PR) interval (abnormally high refers to \>= 210 milliseconds \[msec\]), QRS interval (abnormally Low refers to \<= 50, abnormally high refers to \>= 120 msec) and QT interval (abnormally low refers to \<= 200, abnormally high \>= 500 msec) were reported.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Heart Rate <= 50 bpm | 9 | 2 |
| Heart Rate >= 100 bpm | 3 | 2 |
| PR Duration >= 210 msec | 2 | 2 |
| QRS Duration <= 50 msec | 0 | 0 |
| QRS Duration >= 120 msec | 1 | 0 |
| QT Duration <= 200 msec | 0 | 0 |
| QT Duration >= 500 msec | 0 | 0 |
Pulse oximetry was used to measure arterial SpO2 levels. On each dosing day, the device was attached to the finger, toe, or ear, and SpO2 was monitored and documented. If oxygen saturation levels were less than (\<) 93% at any time during the 1.5 hours postdose interval, pulse oximetry was recorded every 5 minutes until levels return to \>= 93% or until the participant is referred for appropriate medical care, if clinically indicated. Participants with at least 2 consecutive postdose oxygen saturation below 93% during the DB treatment phase were reported.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Number of Participants With Abnormal Arterial Oxygen Saturation (SpO2) Levels (Less Than [<] 93%) as Assessed by Pulse Oximetry at Any Time: DB Treatment Phase | 2 | 3 |
Number of participants with treatment emergent vital signs abnormalities (pulse rate in bpm \[abnormally low = a decrease from baseline of \>= 15 to a value \<= 50; abnormally high = an increase from baseline of \>=15 to a value \>=100\] , systolic blood pressure \[SBP\] in mmHg \[abnormally low = a decrease from baseline of \>= 20 to a value \<= 90; abnormally high = an increase from baseline of \>= 20 to a value \>= 180\], and diastolic blood pressure \[DBP\] in mmHg \[abnormally low= a decrease from baseline of \>=15 to a value \<= 50; abnormally high = an increase from baseline of \>= 15 to a value \>= 105) were reported.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Pulse rate (bpm): Decrease of >=15 to <=50 | 2 | 1 |
| Pulse rate (bpm): Increase of >=15 to >=100 | 11 | 12 |
| SBP: Decrease of >=20 to <=90 | 5 | 2 |
| SBP (mmHg): Increase of >=20 to >=180 | 2 | 3 |
| DBP (mmHg): Decrease of >=15 to <=50 | 4 | 4 |
| DBP (mmHg): Increase of >=15 to >=105 | 3 | 6 |
MOAA/S was used to measure treatment-emergent sedation with correlation to levels of sedation defined by the American society of anesthesiologists (ASA) continuum. The MOAA/S scores range from 0 to 5 where,0 = no response to painful stimulus; ASA continuum = general anesthesia, 1 = responds to trapezius squeeze; ASA continuum = deep sedation, 2 = purposeful response to mild prodding or mild shaking; ASA continuum = moderate sedation, 3 = responds after name called loudly or repeatedly; ASA continuum = moderate sedation, 4 = lethargic response to name spoken in normal tone; ASA continuum = moderate sedation and 5 = readily responds to name spoken in normal tone (awake); ASA continuum = minimal sedation.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Score <=2: Yes | 0 | 4 |
| Score <=3: Yes | 3 | 21 |
| Score <=4: Yes | 20 | 65 |
The CADSS used to measure present-state dissociative symptoms, and to assess treatment-emergent dissociative symptoms. It comprises 23 subjective items divided into 3 components: depersonalization (with score range from 0 to 28), derealization (with score range from 0 to 52), and amnesia (with score range from 0 to 8). Participants responses are coded on a 5-point scale (0 = "Not at all", 1 = "Mild", 2 = "Moderate", 3 = 'Severe" and 4 = "Extreme"). The total score is sum of the 23 items and range from 0 to 92, where 0 (best) and 92 (worst). A higher score indicates a more severe condition. Number of participants with an increase in CADSS total score (increase based on maximum CADSS total score change from predose of \> 0) was reported.
| Participants | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Day 1 | 28 | 106 |
| Day 4 | 21 | 86 |
| Day 8 | 16 | 75 |
| Day 11 | 8 | 68 |
| Day 15 | 11 | 68 |
| Day 18 | 8 | 53 |
| Day 22 | 7 | 58 |
| Day 25 | 4 | 56 |
Collected over Up to Day 25. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Standard of Care (SOC) | 0/113 (0%) | 6/113 (5.3%) | 74/113 (65.5%) |
| Esketamine 84 mg + SOC | 0/114 (0%) | 5/114 (4.4%) | 98/114 (86%) |
| Event | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| Suicide AttemptPsychiatric disorders | 3/113 | 3/114 |
| Suicidal IdeationPsychiatric disorders | 2/113 | 1/114 |
| ArrhythmiaCardiac disorders | 1/113 | 0/114 |
| Pericardial EffusionCardiac disorders | 1/113 | 0/114 |
| DepressionPsychiatric disorders | 1/113 | 0/114 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/113 | 0/114 |
| Depersonalisation/Derealisation DisorderPsychiatric disorders | 0/113 | 1/114 |
| Event | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC |
|---|---|---|
| DizzinessNervous system disorders | 21/113 | 47/114 |
| DissociationPsychiatric disorders | 9/113 | 44/114 |
| NauseaGastrointestinal disorders | 16/113 | 38/114 |
| DysgeusiaNervous system disorders | 18/113 | 29/114 |
| HeadacheNervous system disorders | 26/113 | 25/114 |
| SomnolenceNervous system disorders | 12/113 | 26/114 |
| ParaesthesiaNervous system disorders | 7/113 | 23/114 |
| VomitingGastrointestinal disorders | 5/113 | 18/114 |
| Vision BlurredEye disorders | 6/113 | 17/114 |
| AnxietyPsychiatric disorders | 7/113 | 17/114 |
Full efficacy analysis set included all randomized participants who received at least 1 dose of intranasal study agent during DB treatment phase and had both baseline and post baseline evaluation for Montgomery-Asberg Depression Rating Scale (MADRS) total score or Clinical Global Impression - Severity of Suicidality - Revised (CGI-SS-R).
| Age, Continuous(years) | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC | Total |
|---|---|---|---|
| Mean | 41.4 ± 13.43 | 40.2 ± 12.73 | 40.8 ± 13.07 |
| Sex: Female, Male(Participants) | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC | Total |
|---|---|---|---|
| Female | 67 | 69 | 136 |
| Male | 46 | 45 | 91 |
| Race (NIH/OMB)(Participants) | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 8 | 7 | 15 |
| White | 87 | 92 | 179 |
| More than one race | 6 | 8 | 14 |
| Unknown or Not Reported | 8 | 6 | 14 |
| Region of Enrollment(Participants) | Placebo + Standard of Care (SOC) | Esketamine 84 mg + SOC | Total |
|---|---|---|---|
| ARGENTINA | 9 | 7 | 16 |
| AUSTRIA | 5 | 4 | 9 |
| BELGIUM | 2 | 1 | 3 |
| BRAZIL | 18 | 18 | 36 |
| CANADA | 1 | 0 | 1 |
| CZECH REPUBLIC | 2 | 1 | 3 |
| FRANCE | 9 | 15 | 24 |
| LITHUANIA | 1 | 2 | 3 |
| POLAND | 15 | 18 | 33 |
| SPAIN | 5 | 5 | 10 |
| TURKEY | 10 | 13 | 23 |
| UNITED STATES | 36 | 30 | 66 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Apr 2019, 21 months.
Results were first posted in Sep 2020, 1 year 5 months after primary completion. A results delay was requested in Apr 2020.
Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 21 months is below that.
Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esketamine
Janssen Research & Development, LLC →